Wr. Huckle et al., Effects of L-749,329, an ETA/ETB endothelin receptor antagonist, in a porcine coronary artery injury model of vascular restenosis, CIRCULATION, 103(14), 2001, pp. 1899-1905
Citations number
40
Categorie Soggetti
Cardiovascular & Respiratory Systems","Cardiovascular & Hematology Research
Background-Previous studies in animal models of angioplasty have suggested
a role in neointimal hyperplasia for endothelins (ETs), potent vasoconstric
ting peptides that also exert growth-promoting effects. The present studies
were undertaken to test the hypothesis that endothelin receptor blockade c
an reduce neointimal thickening in injured porcine coronary arteries.
Methods and Results-An ETA/ETB antagonist, L-749,329, was evaluated as an i
nhibitor of intimal thickening in a porcine balloon/stent model of coronary
artery injury. L-749,329 competitively inhibited [I-125]ET-1 binding to po
rcine ETA (IC50 approximate to0.3 nmol/L) or ETB (IC50 approximate to 20 nm
ol/L) receptors and inhibited ET-l-stimulated signaling in cell culture. In
anesthetized pigs, big ET-l-stimulated increases in systemic blood pressur
e were totally inhibited after intravenous infusion of L-749,329 (greater t
han or equal to0.2 mg . kg(-1) . h(-1)). In vascular injury studies, pigs w
ere treated with vehicle or L-749,329 (1 mg . kg(-1) . h(-1)) beginning 2 d
ays before and continuing 28 days after experimental angioplasty. Left ante
rior descending, left circumflex, and/or right coronary arteries were injur
ed by inflation of an angioplasty balloon wrapped with a coiled metallic st
ent. After 28 days, mean neointimal thickness in the L-749,329-treated grou
p was reduced by 9.0% compared with vehicle-treated controls, but this effe
ct was not statistically significant (P=0.13).
Conclusions-Blockade of endothelin receptors for 28 days with only a mixed
ETA/ETB receptor antagonist is insufficient to substantially inhibit intima
l hyperplasia after balloon/stent coronary artery injury in the pig, in con
trast to results with a selective ETA antagonist. The effects of selective
or mixed ETA/ETB antagonists in diseased vessels remain to be determined in
this model.